Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.710
-0.210 (-4.27%)
Dec 5, 2025, 4:00 PM EST - Market closed
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Recursion Pharmaceuticals stock have an average target of 7.25, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 53.93% from the current stock price of 4.71.
Analyst Consensus: Buy
* Price targets were last updated on Sep 11, 2025.
Analyst Ratings
The average analyst rating for Recursion Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +69.85% | Sep 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +69.85% | Jul 8, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $5 | Hold | Initiates | $5 | +6.16% | Jul 3, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $8 → $5 | Hold | Maintains | $8 → $5 | +6.16% | Jun 16, 2025 |
| Needham | Needham | Strong Buy Maintains $11 → $8 | Strong Buy | Maintains | $11 → $8 | +69.85% | May 6, 2025 |
Financial Forecast
Revenue This Year
63.42M
from 58.84M
Increased by 7.79%
Revenue Next Year
80.75M
from 63.42M
Increased by 27.32%
EPS This Year
-1.63
from -1.69
EPS Next Year
-1.28
from -1.63
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 89.8M | 105.0M | |
| Avg | 63.4M | 80.7M | |
| Low | 47.4M | 59.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 52.6% | 65.6% | |
| Avg | 7.8% | 27.3% | |
| Low | -19.5% | -5.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.55 | -1.16 | |
| Avg | -1.63 | -1.28 | |
| Low | -1.70 | -1.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.